|
WASHINGTON (AP) - Federal regulators say MedImmune's nasal spray flu vaccine is effective for children under age 5, even though it may increase the risk of respiratory problems.
The vaccine, Flumist, was once thought to be a possible blockbuster drug, but has had modest sales because approved use is limited to healthy people between the age of 5 and 49 years old.
MedImmune wants Food and Drug Administration approval to market the nasal spray vaccine to young children, which could provide a major revenue boost for the company since the U.S. Centers for Disease Control and Prevention recommends children between 6 months and six years old get an annual influenza virus vaccine.
|